Assess the Oral Bioavailability of New ABT-263 Formulations

NCT00743028 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Lymphomas
Leukemias

Interventions

DRUG: ABT-263
DRUG: ABT-263
DRUG: ABT-263

Sponsor

Abbott

Collaborators

[object Object]